Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).
Toni K. Choueiri(Harvard University), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Brian I. Rini(Vanderbilt University Medical Center), Paul N. Mainwaring(Australasia Paediatric Endocrine Group), Colin Hessel(Exelixis (United States)), Bruce J. Roth, Sumanta K. Pal(City of Hope), Bernard Escudier(Institut Gustave Roussy), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Frede Donskov(Aarhus University Hospital), Jae‐Lyun Lee(Ulsan College), Dana T. Aftab(Exelixis (United States)), Manuela Schmidinger(Medical University of Vienna), Thomas E. Hutson(Texas Tech University), Hans J. Hammers(Southwestern Medical Center), Christian Scheffold(Exelixis (United States)), Thomas Powles(National Health Service), Katriina Peltola, Daniel Yick Chin Heng(University of Calgary), Gisela Schwab(Exelixis (United States))
Cited by 2
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k